Jiangsu Hengrui Medicine Co Ltd (600276)

Currency in CNY
62.03
+0.72(+1.17%)
Closed·
600276 Scorecard
Full Analysis
Impressive gross profit margins
600276 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
60.0062.05
52 wk Range
41.7765.43
Key Statistics
Bid/Ask
62.02 / 62.04
Prev. Close
61.31
Open
60.73
Day's Range
60-62.05
52 wk Range
41.77-65.43
Volume
68.09M
Average Volume (3m)
53.18M
1-Year Change
44.91%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
600276 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
72.24
Upside
+16.46%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Jiangsu Hengrui Medicine Co Ltd Company Profile

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; training; investment advisory; technology development; project; information; and investing services, as well as the import and export of pharmaceutical products. The company has license agreement with GSK plc to develop up to 12 innovative medicines in respiratory, immunology and inflammation, and oncology areas. Jiangsu Hengrui Medicine Co., Ltd. was founded in 1970 and is headquartered in Lianyungang City, China.

Employees
20238
Market
China

Compare 600276 to Peers and Sector

Metrics to compare
600276
Peers
Sector
Relationship
P/E Ratio
59.7x17.5x−0.5x
PEG Ratio
1.070.090.00
Price/Book
8.7x2.5x2.6x
Price / LTM Sales
14.0x3.0x3.3x
Upside (Analyst Target)
14.4%5.7%45.1%
Fair Value Upside
Unlock18.6%7.4%Unlock

Analyst Ratings

21 Buy
2 Hold
1 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 72.24
(+16.46% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.09%
Dividend Yield
0.33%
Industry Median 1.51%
Annualised payout
0.20
Paid annually
5-Years Growth
+4.59%
Growth Streak

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
0.30 / 0.18
Revenue / Forecast
7.21B / 6.33B
EPS Revisions
Last 90 days

600276 Income Statement

People Also Watch

122.90
3690
+0.57%
1,419.00
600519
+0.14%
266.11
300750
+1.16%
27.48
600887
-0.11%
58.21
601318
+0.02%

FAQ

What Stock Exchange Does Jiangsu Hengrui Trade On?

Jiangsu Hengrui is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Jiangsu Hengrui?

The stock symbol for Jiangsu Hengrui is "600276."

What Is the Jiangsu Hengrui Market Cap?

As of today, Jiangsu Hengrui market cap is 410.73B.

What Is Jiangsu Hengrui's Earnings Per Share (TTM)?

The Jiangsu Hengrui EPS (TTM) is 1.09.

When Is the Next Jiangsu Hengrui Earnings Date?

Jiangsu Hengrui will release its next earnings report on 23 Oct 2025.

From a Technical Analysis Perspective, Is 600276 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Jiangsu Hengrui Stock Split?

Jiangsu Hengrui has split 19 times.

How Many Employees Does Jiangsu Hengrui Have?

Jiangsu Hengrui has 20238 employees.

What is the current trading status of Jiangsu Hengrui (600276)?

As of 04 Aug 2025, Jiangsu Hengrui (600276) is trading at a price of 62.03, with a previous close of 61.31. The stock has fluctuated within a day range of 60.00 to 62.05, while its 52-week range spans from 41.77 to 65.43.

What Is Jiangsu Hengrui (600276) Price Target According to Analysts?

The average 12-month price target for Jiangsu Hengrui is CNY72.23875, with a high estimate of CNY123 and a low estimate of CNY50. 21 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +16.46% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.